Higher Expression of Chemokine Receptor CXCR7 Is Linked to Early and Metastatic Recurrence in Pathological Stage I Nonsmall Cell Lung Cancer
Higher Expression of Chemokine Receptor CXCR7 Is Linked to Early and Metastatic Recurrence in Pathological Stage I Nonsmall Cell Lung Cancer
复制标题
DOI：
10.1002/cncr.24281
复制
发表时间：
2009-06-01
期刊：
影响因子：
6.2
通讯作者：
Miyahara, Ryo
中科院分区：
文献类型：
--
作者：
Iwakiri, Shotaro;Mino, Nobuya;Miyahara, Ryo
背景：作者阐明了肺癌细胞上表达的特定趋化因子受体，以及这些趋化因子受体在完全切除的非小细胞肺癌（NSCLC）中表达的临床意义。方法：作者使用定量方法检测了 11 个肺癌细胞系中趋化因子受体（CCP1-11、CXCP1-7、XCP7 和 CX3CP7）的基因表达，以及 2001 年 5 月至 2002 年 12 月期间接受 NSCLC 完全切除的 127 名患者手术标本中 CXCP3、CXCP4 和 CXCP7 (CXCP3/4/7) 的基因表达。实时逆转录聚合酶链反应（PCR）。使用 PCR 单链构象多态性方法对病理性 (p-) I 期腺癌患者进行 EGFP 基因突变检测分析。结果：在所有检查的 NSCLC 细胞系中均观察到 CXCP3/4/7 mRNA 的大量表达。在p期I NSCLC中，术后转移复发（Rec-Distant）患者的CXCP4和CXCP7表达值显着高于未复发患者（分别为P=.003和P=.007）。此外，CXCP7高表达患者的5年无病生存率（63.2%）显着低于CXCP7低表达患者（84.8%）（P=.033）。 CXCP7 表达较高的患者（21 名患者中的 14 名）中 EGFP 突变的频率明显高于 CXCP7 表达较低的患者（32 名患者中的 12 名）（P=.038）。多变量分析证实，CXCP7 高表达是预测 p 期 I NSCLC 患者 DFS 较差的独立且重要的因素 (P=.041)。结论：CXCR7 的较高表达与 p 期 I NSCLC 患者的 Rec-Distant 和较差的 DFS 相关。癌症 2009；115：2580-93。(C) 2009 美国癌症协会。
BACKGROUND: The authors elucidated particular chemokine receptors that are expressed on lung cancer cells, as well as the clinical significance of the expression of these chemokine receptors in completely resected nonsmall cell lung cancer (NSCLC). METHODS: The authors examined gene expression of chemokine receptors (CCP1-11, CXCP1-7, XCP7, and CX3CP7) in 11 cell lines of lung cancer, and gene expression of CXCP3, CXCP4, and CXCP7 (CXCP3/4/7) in surgical specimens of 127 patients who underwent complete resection for their NSCLC between May 2001 and December 2002, using quantitative real-time reverse transcriptase-polymerase chain reaction (PCR). Mutation detection analysis of the EGFP genes using the PCR single-strand conformational polymorphism method was evaluated in patients with pathological (p-) stage I adenocarcinoma. RESULTS: Substantial expression of CXCP3/4/7 mRNA was observed in all NSCLC cell lines examined. In p-stage I NSCLC, CXCP4 and CXCP7 expression values in patients with postoperative metastatic recurrence (Rec-Distant) were significantly higher than in those without recurrences (P=.003 and P=.007, respectively). In addition, the 5-year disease-free survival (DFS) rate of high CXCP7-expressing patients (63.2%) was significantly lower than that of low CXCP7-expressing patients (84.8%) (P=.033). The EGFP mutation was significantly more frequent in patients with higher CXCP7 expression (14 of 21 patients) than in those with lower CXCP7 expression (12 of 32 patients) (P=.038). A multivariate analysis confirmed that high CXCP7 expression was an independent and significant factor predicting a poor DFS in p-stage I NSCLC patients (P=.041). CONCLUSIONS: Higher expression of CXCR7 is associated with Rec-Distant and poor DFS in patients with p-stage I NSCLC. Cancer 2009;115:2580-93.(C) 2009 American Cancer Society.